



*Aldosterone bloCkade for Health Improvement  
Evaluation in End-stage renal disease*

# Background and Study Rationale

- *Globally approximately 2.5 million people receive dialysis for kidney failure*
- *The outcomes for many patients receiving dialysis are poor with a median survival of only 3 years, frequent hospitalizations, and poor health related quality of life*
- *Heart disease is the leading cause of death for patients that require dialysis but there no treatments that are known to effectively reduce heart related deaths and hospitalizations*

# Importance of the ACHIEVE Study

- *Aldosterone is a hormone that may play an important role in causing heart disease*
- *Blocking the actions of aldosterone reduce heart related deaths and hospitalizations in patients with normal kidney function and look promising for patients who have kidney failure treated with dialysis*
- *The ACHIEVE trial will help establish whether blocking aldosterone with a widely available drug called spironolactone prevents heart related deaths and hospitalizations in patients that receive dialysis*

# Eligibility Assessment

## Inclusion Criteria

1. Age
  - a)  $\geq 45$  years
  - or
  - b)  $\geq 18$  with a history of diabetes
2. On dialysis  $\geq 90$  days
3. On either
  - a) Hemodialysis at  $\geq 2$  tx/week
  - or
  - b) Peritoneal dialysis  $\geq 1$  exchange/day
4. Provides informed consent

## Exclusion Criteria

1. Hyperkalemia
  - a) Serum potassium  $> 5.8$  mmol/L in 6 weeks prior
  - or
  - b) Serum potassium  $> 6.0$  mmol/L during active run-in
2. Currently taking & unable to withdraw MRA
3. Known sensitivity or allergy to spironolactone
4. Current or planned pregnancy or breastfeeding
5. Scheduled living related donor renal transplant
6. Life expectancy  $< 6$  months in the opinion of a treating nephrologist
7. Enrolled in another interventional trial testing a MRA or drug that has a known/likely interaction with spironolactone

# Study Flow Diagram

